tiprankstipranks
Cellectar Reports Promising iopofosine Study Results
Company Announcements

Cellectar Reports Promising iopofosine Study Results

Don't Miss our Black Friday Offers:

An announcement from Cellectar Biosciences (CLRB) is now available.

On July 23, 2024, the Company shared uplifting results from its CLOVER WaM study focused on iopofosine I 131 for treating relapsed/refractory Waldenstrom’s macroglobulinemia. Demonstrating an impressive 80% overall response rate and 56.4% major response rate among patients previously treated with at least two therapy lines, the study surpassed its primary endpoint. The findings also highlighted durable responses across various patient subgroups, irrespective of mutation status or prior treatments, indicating iopofosine’s potential as a promising therapy option for this challenging condition.

Learn more about CLRB stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCellectar Biosciences price target lowered to $12 from $14 at Oppenheimer
TipRanks Auto-Generated NewsdeskCellectar Biosciences Reports Q3 2024 Financial Results
TheFlyCellectar Biosciences reports Q3 EPS (40c), consensus (37c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App